Data Reported From Phase 1 Study of Once a Week MLN9708 Oral Proteasome Inhibitor in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis
17:30 EST 10 Dec 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Millennium:
The Takeda Oncology Company with its parent company Takeda
Pharmaceutical Company Limited (TSE:4502) today announced the
presentation of data from a phase 1 study investigating once a week
MLN9708 in patients ...
Other Sources for this Article
Millennium
Manisha Pai, +1-617-551-7877
Manisha.pai@mpi.com
or
David
Albaugh, +1-617-444-4456
david.albaugh@mpi.com
or
Takeda
Pharmaceutical Company Limited
Corporate Communications Dept.
(PR/IR)
Tel: +81-3-3278-2037
More From BioPortfolio on "Data Reported From Phase 1 Study of Once a Week MLN9708 Oral Proteasome Inhibitor in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
